Nootropic Heptapeptide
An ACTH-Derived Peptide with Selective Neurotropic Activity
Semax is a synthetic heptapeptide based on the 4-10 fragment of adrenocorticotropic hormone (ACTH). It was originally developed in Russia for neuroprotective applications and has since become a research tool for studying neurotrophin signaling — specifically the upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). A key characteristic that distinguishes it from its parent molecule is its lack of effect on the adrenal axis: Semax does not alter cortisol levels, allowing neurological effects to be studied without confounding hormonal interference.
- Synthetic heptapeptide: Met-Glu-His-Phe-Pro-Gly-Pro
- Derived from the 4-10 fragment of ACTH
- Upregulates BDNF, NGF, serotonin, and dopamine
- No effect on cortisol or adrenal hormone secretion
- Gene expression changes detectable within 20 minutes of administration
For laboratory research use only. Not for human consumption.
Default Mode Network & Neuroplasticity
BDNF Induction, Default Mode Network Activation and Gene Regulation
One of Semax's most documented neurological effects is its activation of the brain's default mode network (DMN) — the distributed neural system involved in environmental monitoring, attentional readiness, and social cognition. Functional imaging studies have shown that Semax enhances DMN connectivity, which is associated with more fluid transitions between resting and focused cognitive states. At the molecular level, a single administration has been shown to alter the expression of genes governing vascular tone and neuroplasticity in the hippocampus and frontal cortex — regions central to learning, memory, and executive function.
- Activates default mode network — confirmed by functional imaging studies
- Enhances transition efficiency between rest and focused cognitive states
- Increases neural interconnectivity across brain regions
- Modulates expression of genes related to vascular and neural function
- Rapid gene expression changes in hippocampus and frontal cortex
For laboratory research use only. Not for human consumption.
Research Applications
Neuroprotection, Cognitive Research and Mood Disorder Biology
Semax has been studied across a broad range of neurological research contexts. Its most established application is in stroke and ischemic injury models, where BDNF elevation and neuroplasticity support have been linked to improved functional recovery. In mood disorder research, its BDNF-stimulating properties have positioned it as a tool for investigating the neurobiological basis of depression — including the hypothesis that BDNF deficiency underlies the delayed therapeutic onset of conventional antidepressants. Additional research areas include optic nerve inflammation, immune-neural signaling, and cognitive protection in seizure models.
- Stroke and ischemia: Neuroprotection and functional recovery modeling
- Neuroplasticity: BDNF and NGF upregulation studies
- Depression research: Neurotrophin pathway and mood biology
- Cognitive function: Learning, memory, and attention research
- Optic nerve inflammation and neuroimmune signaling
For laboratory research use only. Not for human consumption.
Semax: Neurotrophin Signaling and Cognitive Research Without Adrenal Interference
Semax occupies a distinctive position in neuropeptide research. Derived from the 4-10 fragment of ACTH but structurally modified to eliminate adrenal axis activity, it provides a selective tool for investigating neurotrophin signaling — particularly the BDNF and NGF pathways — without the cortisol variability that would otherwise complicate experimental interpretation. This separation of neurotropic from endocrine effects is one of its key research advantages.
At the cellular level, Semax administration produces rapid changes in gene expression in regions of the brain most relevant to cognition and emotional regulation. In the hippocampus and prefrontal cortex, upregulation of BDNF and NGF transcription has been documented within minutes, with downstream effects on synaptic plasticity, dendritic remodeling, and neuronal survival. These findings are particularly relevant to research on learning and memory consolidation, where neurotrophins play a well-established role.
Functional imaging research has added another dimension to Semax's research profile. Its documented activation of the default mode network — a system critically involved in attentional readiness, self-referential processing, and social cognition — makes it relevant to studies on conditions where DMN function is disrupted, including Alzheimer's disease, depression, and ADHD. Increased DMN connectivity has been associated with cognitive flexibility and the capacity to shift between internally and externally directed thought.
In applied research models, Semax has demonstrated neuroprotective effects in ischemic injury contexts, supporting neuronal survival and accelerating functional recovery through BDNF-dependent mechanisms. Its relevance to depression research stems from the observation that BDNF normalization may underlie the delayed clinical response to SSRIs — a hypothesis that Semax's rapid neurotrophin-stimulating profile helps to test directly. For teams investigating neuroprotection, cognitive biology, neuroplasticity, or mood disorder mechanisms, Semax provides a well-characterized, adrenal-silent research compound with decades of documented activity across multiple neurological endpoints.
For research use only. Not for human consumption.